Marie Mura, Aurélie Trignol, Erwan Le Dault, Jean-Nicolas Tournier
{"title":"Lessons for medical countermeasure development from unforeseen outbreaks.","authors":"Marie Mura, Aurélie Trignol, Erwan Le Dault, Jean-Nicolas Tournier","doi":"10.1080/22221751.2025.2471035","DOIUrl":"10.1080/22221751.2025.2471035","url":null,"abstract":"<p><p>The unanticipated emergence of the COVID-19 pandemic and the rapid spread of the mpox epidemic in 2022 and 2024 brought unforeseen challenges to public health. While distinct in nature, these outbreaks share some similarities and offer valuable insights into responding to novel virus dissemination in vulnerable populations. In light of these two experiences, we aim to discern the prioritization of medical countermeasures (MCM) among antivirals, antibodies, and vaccines. Comparative analysis of MCMs reveals that while antivirals serve essential roles as therapeutic tools, monoclonal antibodies can be used for both prevention and treatment, and vaccines remain of paramount importance for controlling epidemics as mass or targeted prophylaxis. Variability in production processes, administration methods, logistics, and costs distinguish these countermeasures. Vaccines, by inducing long-lasting immunity and ideally promoting herd effects, exhibit substantial advantages over other options. To enhance future pandemic readiness, proactive measures must include ready-to-use vaccine platforms with regulatory approval and manufacturing capacities, as well as prototype vaccines for representative pathogens and preexisting protocols to evaluate their efficacies and side effects. The comparison underscores the challenges of social acceptance and equity, particularly in vaccine production and distribution. As the world faces unknown agents, the three major types of MCMs do not have equal and symmetrical effects in terms of epidemic control. Thus, a vaccine-oriented strategy with a community-centered approach, proves essential for effective pandemic preparedness, encouraging continued innovation in vaccinology.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2471035"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Thonningianin A disrupts pA104R-DNA binding and inhibits African swine fever virus replication.","authors":"Quan-Jie Li, Hui-Han Shao, Lin-Lin Zheng, Qian Liu, Chen-Chao Huo, Dong-Rong Yi, Tao Feng, Shan Cen","doi":"10.1080/22221751.2025.2482697","DOIUrl":"10.1080/22221751.2025.2482697","url":null,"abstract":"<p><p>African swine fever is a highly lethal disease caused by the African swine fever virus (ASFV), posing a significant threat to the global pig industry, wherease no approved treatments are currently available. The ASFV DNA-binding protein, pA104R, plays a critical role in viral genome packaging and replication, making it a key target for drug discovery. Through structure-based virtual screening, we identified a polyphenolic compound, thonningianin A, which disrupts the pA104R-DNA binding and significantly inhibits ASFV replication. Mechanistic study revealed that thonningianin A binds to the DNA-binding region of pA104R, forming strong hydrogen bonds with H100 and occupying the vital DNA-binding residues K92, R94, and K97. In addition, we resolved the high-resolution (1.8 Å) structure of pA104R (PDB ID 9JS5), providing valuable insights for future drug screening. Together, these results demonstrate that thonningianin A holds great potential for the development of anti-ASFV drug, as a herb extract with favourable pharmacokinetic properties and safety.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2482697"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"GNLY+CD8+ T cells bridge premature aging and persistent inflammation in people living with HIV.","authors":"Hui-Fang Wang, Chao Zhang, Li-Ping Zhang, Cheng Zhen, Liang Zhao, Hui-Huang Huang, Bao-Peng Yang, Si-Yuan Chen, Wei-Zhe Li, Ming-Ju Zhou, Qian-Xi Guo, Xia Li, Bai-Lu Yin, Fang Sun, Ji-Yuan Zhang, Zhixin Zhang, Fu-Sheng Wang, Qing-Lei Zeng","doi":"10.1080/22221751.2025.2466695","DOIUrl":"10.1080/22221751.2025.2466695","url":null,"abstract":"<p><p>People living with HIV (PLWH) exhibit accelerated aging, characterized by systemic inflammation, termed \"inflammaging.\" While T-cell expansion is prevalent in PLWH, its connection to inflammaging remains unclear. In this study, we analyzed the TCRβ repertoire of 257 healthy controls (HC) and 228 PLWH, revealing pronounced T cell clonal expansion in PLWH. The expansion was only partially reversed following antiretroviral therapy (ART) and closely associated with ART duration, CD4+ T and CD8+ T cell counts and the CD4/CD8 ratio. TCR-based age modeling showed a continuous accelerated trajectory of aging in PLWH, especially in younger individuals, in stark contrast to the nonlinear aging acceleration pattern seen in HC. Furthermore, using single-cell RNA combined TCR sequencing and in vitro experiments, we identified GNLY+CD8+ T cells as the primary population driving clonal expansion and maintenance in PLWH. These cells are characterized by high cytotoxicity and low exhaustion and are activated by interleukin-15 (IL-15) in vitro. Notably, GNLY+CD8+ T cells predominantly express the pro-inflammatory 15 kDa form of granulysin(GNLY). The supernatant from IL-15-stimulated CD8+ T cells induces monocytes to secrete inflammatory factors and disrupts the integrity of intestinal epithelial cells, which can be partially restored by the anti-GNLY antibodies. These findings identify GNLY+CD8+ T cells as the central drivers of persistent clonal expansion, highlighting their crucial role for mitigating inflammaging in PLWH.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":"14 1","pages":"2466695"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An attenuated African swine fever virus expressing the E2 glycoprotein of classical swine fever virus protects pigs against challenge of both viruses.","authors":"Jiwen Zhang, Fang Li, Weiye Chen, Yongfeng Li, Zhenjiang Zhang, Ronghong Hua, Renqiang Liu, Yuanmao Zhu, Encheng Sun, Huaji Qiu, Zhigao Bu, Dongming Zhao","doi":"10.1080/22221751.2025.2469636","DOIUrl":"10.1080/22221751.2025.2469636","url":null,"abstract":"<p><p>African swine fever (ASF) and classical swine fever (CSF) are highly contagious diseases with high morbidity and mortality rates resulting in an enormous impact on the global pig industry. A bivalent vaccine that simultaneously protects against both ASF and CSF is highly desirable. We previously developed a seven-gene-deleted African swine fever virus (ASFV) attenuated vaccine candidate (HLJ/18-7GD) that provides complete protection against homologous strains. Herein, we constructed a recombinant virus HLJ/18-7GD-E2 by inserting the classical swine fever virus (CSFV) E2 gene into the HLJ/18-7GD via homologous recombination. After continuous <i>in vitro</i> passaging, Western blotting analysis showed that the E2 gene was expressed and stably maintained within the ASFV genome. Next, the immunogenicity and protective efficacy of the recombinant HLJ/18-7GD-E2 virus was evaluated in pigs. The results revealed that a single dose of 10<sup>6</sup> TCID<sub>50</sub> of HLJ/18-7GD-E2 induced an efficient immune response and provided complete protection against lethal challenges with ASFV or CSFV. These results demonstrate that recombinant ASFV expressing the CSFV E2 protein has potential as a bivalent live attenuated vaccine, providing solid protection against ASFV and CSFV infection in pigs.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2469636"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Daouda Abba Moussa, Mario Vazquez, Christine Chable-Bessia, Vincent Roux-Portalez, Elia Tamagnini, Mattia Pedotti, Luca Simonelli, Giang Ngo, Manon Souchard, Sebastien Lyonnais, Myriam Chentouf, Nathalie Gros, Soledad Marsile-Medun, Heiko Dinter, Martine Pugnière, Pierre Martineau, Luca Varani, Manel Juan, Hugo Calderon, Mar Naranjo-Gomez, Mireia Pelegrin
{"title":"Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches.","authors":"Daouda Abba Moussa, Mario Vazquez, Christine Chable-Bessia, Vincent Roux-Portalez, Elia Tamagnini, Mattia Pedotti, Luca Simonelli, Giang Ngo, Manon Souchard, Sebastien Lyonnais, Myriam Chentouf, Nathalie Gros, Soledad Marsile-Medun, Heiko Dinter, Martine Pugnière, Pierre Martineau, Luca Varani, Manel Juan, Hugo Calderon, Mar Naranjo-Gomez, Mireia Pelegrin","doi":"10.1080/22221751.2024.2432345","DOIUrl":"10.1080/22221751.2024.2432345","url":null,"abstract":"<p><p>Unlocking the potential of broadly reactive coronavirus monoclonal antibodies (mAbs) and their derivatives offers a transformative therapeutic avenue against severe COVID-19, especially crucial for safeguarding high-risk populations. Novel mAb-based immunotherapies may help address the reduced efficacy of current vaccines and neutralizing mAbs caused by the emergence of variants of concern (VOCs). Using phage display technology, we discovered a pan-SARS-CoV-2 mAb (C10) that targets a conserved region within the receptor-binding domain (RBD) of the virus. Noteworthy, C10 demonstrates exceptional efficacy in recognizing all assessed VOCs, including recent Omicron variants. While C10 lacks direct neutralization capacity, it efficiently binds to infected lung epithelial cells and induces their lysis via natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Building upon this pan-SARS-CoV-2 mAb, we engineered C10-based, Chimeric Antigen Receptor (CAR)-T cells endowed with efficient killing capacity against SARS-CoV-2-infected lung epithelial cells. Notably, NK and CAR-T-cell mediated killing of lung infected cells effectively reduces viral titers. These findings highlight the potential of non-neutralizing mAbs in providing immune protection against emerging infectious diseases. Our work reveals a pan-SARS-CoV-2 mAb effective in targeting infected cells and demonstrates the proof-of-concept for the potential application of CAR-T cell therapy in combating SARS-CoV-2 infections. Furthermore, it holds promise for the development of innovative antibody-based and cell-based therapeutic strategies against severe COVID-19 by expanding the array of therapeutic options available for high-risk populations.<b>Trial registration:</b> ClinicalTrials.gov identifier: NCT04093596.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2432345"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Grand Challenges on HIV/AIDS in China - The 5th Symposium, Yunnan 2024.","authors":"Zhiwei Chen, Jianqing Xu, Xia Jin, Jianhua Wang, Jinghe Huang, Hui Zhang, Ling Chen, Kai Deng, Weiping Cai, Linghua Li, Fusheng Wang, Zhiwei Wu, Hong Shang, Hao Wu","doi":"10.1080/22221751.2025.2492208","DOIUrl":"10.1080/22221751.2025.2492208","url":null,"abstract":"<p><p>HIV-1 infection has led to 1.329 million people living with the virus and 0.474 millions of deaths by the middle of 2024 in China. Achieving the goal of ending HIV/AIDS in China by 2030 has faced several grand challenges including currently having a diagnostic rate of less than 85%, an estimated annual cost burden of 6.3 billion RMB for antiretroviral therapy (ART) alone, and the lack of therapeutic cure and preventive vaccine and so on. To address these challenges, Chinese scientists initiated the programme of <i>Grand Challenges on HIV/AIDS in China</i> (GCC) in 2017. The inauguration symposium was held from 30 November to 1 December 2017 in Hong Kong - Asia's World City - to commemorate the 10th anniversary of AIDS Institute at The University of Hong Kong and Comprehensive AIDS Research Center at Tsinghua University. The mission of the GCC is to advance HIV/AIDS prevention, prioritize research on therapeutic cure and vaccine, disseminate new scientific findings, and foster broader collaborations. Following the inaugural event, subsequent symposia were held at Fudan University in 2018, Sun Yat-Sen University in 2019, Tsinghua University in 2023, and Dali University in 2024. This review reports the scientific presentations and progresses made by the GCC scientists, highlighting efforts to combat HIV/AIDS in China.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2492208"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peilan Wei, Ruoxi Cai, Lu Zhang, Jingjun Zhang, Zhaoyong Zhang, Airu Zhu, Hai Li, Zhen Zhuang, Lan Chen, Jiantao Chen, Yuting Zhang, Xinyi Xiong, Bin Qu, Jianfen Zhuo, Tian Tang, Yuanyuan Zhang, Lei Chen, Qier Zhong, Zhiwei Lin, Xindan Xing, Fang Li, Qingtao Hu, Jun Dai, Yongxia Shi, Jingxian Zhao, Jincun Zhao, Yanqun Wang
{"title":"<i>In vivo</i> determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models.","authors":"Peilan Wei, Ruoxi Cai, Lu Zhang, Jingjun Zhang, Zhaoyong Zhang, Airu Zhu, Hai Li, Zhen Zhuang, Lan Chen, Jiantao Chen, Yuting Zhang, Xinyi Xiong, Bin Qu, Jianfen Zhuo, Tian Tang, Yuanyuan Zhang, Lei Chen, Qier Zhong, Zhiwei Lin, Xindan Xing, Fang Li, Qingtao Hu, Jun Dai, Yongxia Shi, Jingxian Zhao, Jincun Zhao, Yanqun Wang","doi":"10.1080/22221751.2025.2459140","DOIUrl":"10.1080/22221751.2025.2459140","url":null,"abstract":"<p><p>Neutralizing antibody titres have been shown to correlate with immune protection against COVID-19 and can be used to estimate vaccine effectiveness. Numerous studies have explored the relationship between neutralizing antibodies and protection. However, there remains a lack of quantitative data directly assessing the minimum effective protective neutralizing antibody titre in <i>in vivo</i>. In this study, we utilized eight cohorts of participants with diverse immune backgrounds for evaluation of protective antibody response. To precisely assess the lower threshold of neutralizing antibody titres required for effective protection against SARS-CoV-2 infections, we employed plasma adoptive transfer from different cohorts into mice. This study demonstrated that neutralizing titres in the plasma of recipient mice correlated well with those in human donors, and a positive linear correlation was observed between the human and mouse recipients of transferred plasma neutralizing titre. A pseudotyped virus neutralizing titres greater than 7 was identified as the minimum threshold necessary to reduce viral titres in infected mice, establishing a crucial baseline for effective protection. Furthermore, despite the variability in immune backgrounds, these diverse cohorts' plasma exhibited a similar neutralizing antibody threshold necessary for protection. This finding has significant implications for vaccine design and the assessment of immune competence.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2459140"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143032629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical manifestations and pathogenicity of Clade IIb monkeypox virus in rabbits.","authors":"Chao Shang, Shaowen Shi, Qiwei Jiang, Xiaohan Wang, Xiaohong Yao, Wanzi Li, Gaojie Song, Yiquan Li, Yongyang Sun, Jinglei Hu, Cuiling Zhang, Yilong Zhu, Zirui Liu, Chaode Gu, Yan Liu, Wanyu Shi, Zongzheng Zhao, Xiao Li","doi":"10.1080/22221751.2025.2465309","DOIUrl":"10.1080/22221751.2025.2465309","url":null,"abstract":"<p><p>The 2022 monkeypox outbreak involved rapid global dissemination, prompting research into animal models for the monkeypox virus (MPXV), including non-human primates and mice. However, studies utilizing rabbits as models remain limited. In this study, we established three rabbit models using the current epidemic MPXV strain. Following intravenous MPXV injection, adult rabbits exhibited characteristic clinical manifestations, including widespread rash and fever, with viral replication in the skin, lungs, and testes, resulting in severe pathological damage by 6 days post-infection (dpi). Intradermal injection of MPXV into the dorsal skin of adult rabbits produced red lesions with central necrosis and hemorrhage accompanied by dense inflammatory infiltrates. Abundant viral particles were observed in epidermal cells at 6 dpi. Additionally, a fatal MPXV model was developed in 10-day-old rabbits using intranasal virus administration. These young rabbits exhibited lethargy and diarrhea beginning at 2 dpi, significant weight loss, and a 50% mortality rate by 15 dpi. Viral dissemination was detected in multiple organs, leading to extensive multi-organ damage. This study highlights the utility of rabbit models for MPXV, displaying typical clinical features and pathogenic mechanisms.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2465309"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dongning Jin, Linliang Zhang, Cheng Peng, Mingbin He, Weiwei Wang, Zhifei Li, Cong Liu, Jinhong Du, Jin Zhou, Lei Yin, Chao Shan, Yali Qin, Mingzhou Chen
{"title":"The E3 ligase RAD18-mediated ubiquitination of henipavirus matrix protein promotes its nuclear-cytoplasmic trafficking and viral egress.","authors":"Dongning Jin, Linliang Zhang, Cheng Peng, Mingbin He, Weiwei Wang, Zhifei Li, Cong Liu, Jinhong Du, Jin Zhou, Lei Yin, Chao Shan, Yali Qin, Mingzhou Chen","doi":"10.1080/22221751.2024.2432344","DOIUrl":"10.1080/22221751.2024.2432344","url":null,"abstract":"<p><p>The nuclear-cytoplasmic trafficking of matrix proteins (M) is essential for henipavirus budding, with M protein ubiquitination playing a pivotal role in this dynamic process. Despite its importance, the intricacies of the M ubiquitination cascade have remained elusive. In this study, we elucidate a novel mechanism by which Nipah virus (NiV), a highly pathogenic henipavirus, utilizes a ubiquitination complex involving the E2 ubiquitin-conjugating enzyme RAD6A and the E3 ubiquitin ligase RAD18 to ubiquitinate the virus's M protein, thereby facilitating its nuclear-cytoplasmic trafficking. We demonstrate that RAD18 interacts with RAD6A, enabling the latter to supply ubiquitins for the RAD18-mediated transfer of ubiquitin to M through RAD18-M interactions. Specifically, M is ubiquitinated by the RAD6A-RAD18 complex at lysine (K) 258 through a K63-linked ubiquitination, a modification crucial for M's function. This ubiquitination drives M's relocation to the cytoplasm, directing it to plasma membranes for effective viral egress. Conversely, disrupting the RAD6A-RAD18-M axis, mutating RAD18's E3 ligase activity, or inhibiting RAD6A activity with TZ9 (a RAD6-ubiquitin thioester formation inhibitor) impairs M ubiquitination, resulting in defective nuclear export and budding of NiV. Significantly, live NiV and Hendra virus infection is attenuated in RAD18 knockout cells or in cells treated with TZ9, highlighting the critical physiological role of RAD6A-RAD18-mediated M ubiquitination in the henipavirus life cycle. Our findings not only reveal how NiV manipulates a nucleus-localized ubiquitination complex to promote virus's M protein ubiquitination and nuclear export, but also suggest that the small molecule inhibitor TZ9 could serve as a potential therapeutic against henipavirus infection.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":" ","pages":"2432344"},"PeriodicalIF":8.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
